Embla Medical (EMBLA) SEB Nordic Seminar presentation summary

Company overview and strategy

• Global leader in mobility solutions, operating ~200 patient care facilities in 11 markets and direct sales in ~40 markets with 4,500 employees.

• Invested $40m in R&D in 2024, about 5% of group sales, with a focus on prosthetics and neuro orthotics.

• Listed on Nasdaq Copenhagen with a market cap over $2bn and recognized for sustainable growth by TIME Magazine.

• Growth'27 strategy targets 7-10% LCY growth, including 2-3% from M&A, and gradual EBITDA margin improvement.

• Achieved highest ever sales in 2024 at $855m, with a 20% EBITDA margin before special items.

Market trends and business segments

• Operates in a niche industry supported by aging populations, improved treatments, better healthcare access, and digitalization.

• 90% of sales come from developed markets, but emerging markets represent over 80% of new amputee volume.

• Business areas include prosthetics, neuro orthotics, bracing & supports, and patient care clinics.

• Americas and EMEA each account for 46% of 2024 sales, with APAC at 8%.

• Prosthetics and neuro orthotics sales include premium devices and innovative orthotic joints.

Financial performance and growth drivers

• Organic sales growth reached 6% in 2024, with total sales of $855m.

• EBITDA margin improved to 20% in 2024, up 2 percentage points from 2023.

• Growth'27 ambitions include 7-10% LCY sales growth and 20-21% EBITDA margin for 2025.

• Q3 2025 saw double-digit growth in prosthetics & neuro orthotics, strong EMEA momentum, and profit growth.

• Closed a 51% investment in Streifeneder ortho.production and launched new products like Odyssey iQ.